Humira Reduces Early Ulcerative Colitis Features, Trial Analysis Shows

Humira Reduces Early Ulcerative Colitis Features, Trial Analysis Shows
AbbVie's Humira (adalimumab) reduces early tissue inflammation, rectal bleeding, and stool frequency in patients with ulcerative colitis, according to a post-hoc analysis of two Phase 3 trials. Findings were published in the study, "Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials," were published in the Journal of Crohn's and Colitis
Subscribe or to access all post and page content.